Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 2/2001

01-04-2001

The reliability of immunohistochemistry as a prescreening method for the diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) – Results of an international collaborative study

Authors: Wolfram Müller, Lawrence J. Burgart, Ruth Krause-Paulus, Stephen N. Thibodeau, M. Almeida, T. Brocker Edmonston, C. R. Boland, C. Sutter, J. R. Jass, A. Lindblom, J. Lubinski, K. MacDermot, D. S. A. Sanders, H. Morreau, A. Müller, C. Oliani, T. Orntoft, M. Ponz De Leon, C. Rosty, M. Rodriguez-Bigas, J. Rüschoff, A. Ruszkiewicz, J. Sabourin, R. Salovaara, Gabriela Möslein

Published in: Familial Cancer | Issue 2/2001

Login to get access
Metadata
Title
The reliability of immunohistochemistry as a prescreening method for the diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) – Results of an international collaborative study
Authors
Wolfram Müller
Lawrence J. Burgart
Ruth Krause-Paulus
Stephen N. Thibodeau
M. Almeida
T. Brocker Edmonston
C. R. Boland
C. Sutter
J. R. Jass
A. Lindblom
J. Lubinski
K. MacDermot
D. S. A. Sanders
H. Morreau
A. Müller
C. Oliani
T. Orntoft
M. Ponz De Leon
C. Rosty
M. Rodriguez-Bigas
J. Rüschoff
A. Ruszkiewicz
J. Sabourin
R. Salovaara
Gabriela Möslein
Publication date
01-04-2001
Publisher
Kluwer Academic Publishers
Published in
Familial Cancer / Issue 2/2001
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1023/A:1013840907881

Other articles of this Issue 2/2001

Familial Cancer 2/2001 Go to the issue

OriginalPaper

Chemotherapy resistant ovarian cancer in carriers of an hMSH2 mutation?

OriginalPaper

Desmoid tumour in familial adenomatous polyposis. A review of literature

OriginalPaper

Familial breast cancer: an investigation into the outcome of treatment for early stage disease

Commentary

Commentary on Eccles et al.: Familial breast cancer: an investigation into the outcome of treatment for early stage disease

OriginalPaper

Café-au-lait spots and early onset colorectal neoplasia: a variant of HNPCC?

OriginalPaper

Preventive measures in Peutz-Jeghers syndrome
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits